|
|
|
25.06.25 - 12:51
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange (GlobeNewswire EN)
|
|
|
SHENZHEN, CHINA, June 25, 2025 (GLOBE NEWSWIRE) -- The board of directors of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces the proposed secondary listing of the Company's ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) by way of introduction (the “Proposed Secondary Listing”). The Proposed Secondary Listing, if proceeded, will not involve issuance of new shares, and the Shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter....
|
|
|
|
|
|
|
|
|
05.06.25 - 07:15
|
Research: UOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating (AAStocks)
|
|
|
According to a report issued by UOB Kay Hian, HANSOH PHARMA (03692.HK) has received approval for two new indications for Ameile and market approval for NSCLC indication in the UK.Meanwhile, HANSOH PHARMA's Hengmeida, which is used for the treatment of candidiasis, has been granted a drug registration certificate by China'......
|
|
|
29.05.25 - 14:33
|
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET....
|
|
|
|
|
|
|
|
|
|
|
06.05.25 - 09:45
|
Research: UOB Kay Hian: Buy List Adds BABA-W, INNOVENT BIO, TRIP.COM-S (AAStocks)
|
|
|
UOB Kay Hian’s report noted that the HSI and MSCI China Index sagged 4.3% and 5.2%, respectively, in April, wrought by U.S. President Donald Trump’s tariff announcements and concerns over a potential global recession. Amid ongoing external uncertainties, UOB Kay Hian will maintain allocations to domestic policy benef......
|
|
|
01.05.25 - 14:33
|
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates....
|
|
|
|
|
28.04.25 - 22:09
|
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire EN)
|
|
|
SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates....
|
|
|
|
|
|
|
27.03.25 - 09:15
|
Research: UOB Kay Hian Lifts WUXI BIO TP to $35, Rating Buy (AAStocks)
|
|
|
WUXI BIO (02269.HK)'s 2024 results beat expectations, with revenue hiking 9.6% YoY and adjusted net profit growing 1.8% YoY, UOB Kay Hian released a research report saying.Benefiting from the substantial increase in new projects and the continuous expansion of revenue scale of phase III and commercialized projects, the Compa......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
